Genitourinary Cancer
News
Sperm counts largely stable after adjuvant treatment of clinical stage I testicular cancer
Sperm count and concentration remained stable or increased in patients with clinical stage I testicular cancer who underwent unilateral...
Conference Coverage
First-line avelumab/axitinib for RCC benefits wide range of patients
SAN FRANCISCO – Subgroup analyses of the JAVELIN Renal 101 trial show that first-line avelumab/axitinib yields better PFS and ORRs than sunitinib...
News
Poor-prognosis cancers linked to highest suicide risk in first year
Pancreatic and lung cancer patients had high rates of suicide in comparison to the general population, while breast and prostate cancer patients...
Conference Coverage
Abiraterone also benefits low-risk metastatic prostate cancer patients
MUNICH – Analyses of STAMPEDE trial data using risk criteria from two other trials revealed distinct survival benefits with abiraterone, ADT, and...
Conference Coverage
Checkpoint inhibitor/TKI combo improves PFS of RCC over sunitinib
MUNICH – Avelumab and axitinib offered better progression-free survival than did sunitinib as first-line therapy for advanced renal cell carcinoma...
Audio
ACS: Screen for colon cancer at 45
And testosterone therapy may impact kidney stone risk.
News
Gene profile predicts RCC response to nivolumab
Many patients with advanced RCC have tumors that do not respond to immune checkpoint inhibitors targeted against the programmed death-1 (PD-1)...
News
SU2C announces researcher-industry collaboration on immunotherapy
News
Pembrolizumab paired with immunostimulator is safe and tolerable
Combining an immunostimulator with pembrolizumab had good tolerability and safety, in a small phase Ib study.